Form 4: Director Robert McQuade Receives COMPASS Pathways Options

Director Robert McQuade was granted 21,110 share options in COMPASS Pathways plc as part of an equity compensation award.

Summary

• Director Robert McQuade acquired 21,110 share options in COMPASS Pathways plc (CMPS).
• The options have an exercise price of $11.85 per share.
• The grant date for these options is May 27, 2026.
• The options are set to expire on May 26, 2036.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which is neutral in terms of immediate market impact.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• Potential future dilution of existing shareholders upon the exercise of these options.

Risks

• Market volatility affecting the value of the underlying ordinary shares.
• The exercise price of $11.85 may be higher than future market prices, rendering the options underwater.

Future Outlook

The options vest in full on the earlier of the first anniversary of the grant date or the 2027 Annual General Meeting of Shareholders.

Industry Context

StockSavvy.ai notes that equity grants to non-executive directors are standard practice in the biotechnology sector to incentivize long-term oversight and strategic alignment.

Comparison to Industry Standards

• The grant of stock options to directors is consistent with standard corporate governance practices for NASDAQ-listed biotech firms.
• Vesting schedules tied to annual general meetings are common among UK-incorporated companies listed in the U.S.

Stakeholder Impact

• Shareholders may experience minor dilution if these options are exercised in the future.

Next Steps

• Vesting of options on May 27, 2027, or the 2027 Annual General Meeting.

Key Dates

Keywords

COMPASS Pathways, CMPS, Form 4, Insider Trading, Equity Compensation, Director Stock Options